Compare BAH & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BAH | KRYS |
|---|---|---|
| Founded | 1914 | 2015 |
| Country | United States | United States |
| Employees | 31500 | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 10.3B |
| IPO Year | 2010 | 2017 |
| Metric | BAH | KRYS |
|---|---|---|
| Price | $60.78 | $364.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 11 |
| Target Price | $97.00 | ★ $297.60 |
| AVG Volume (30 Days) | ★ 2.1M | 310.2K |
| Earning Date | 05-22-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.09% | N/A |
| EPS Growth | N/A | ★ 128.00 |
| EPS | ★ 6.90 | 1.83 |
| Revenue | ★ $11,217,000,000.00 | $389,130,000.00 |
| Revenue This Year | N/A | $38.74 |
| Revenue Next Year | $2.14 | $32.53 |
| P/E Ratio | ★ $8.66 | $196.81 |
| Revenue Growth | N/A | ★ 33.94 |
| 52 Week Low | $59.63 | $130.50 |
| 52 Week High | $120.05 | $362.40 |
| Indicator | BAH | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 24.54 | 75.20 |
| Support Level | N/A | $253.89 |
| Resistance Level | $82.42 | N/A |
| Average True Range (ATR) | 2.73 | 12.58 |
| MACD | -1.77 | 3.65 |
| Stochastic Oscillator | 6.62 | 89.65 |
Booz Allen Hamilton Holding Corp provides technology solutions in areas such as artificial intelligence, cybersecurity, and related fields. The company serves U.S. federal government agencies, commercial clients, and select international customers. It also provides technologies to evolve defense missions and delivers solutions to warfighters in the digital battlespace.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.